Memantine


Article Author:
Brianne Kuns


Article Editor:
Dona Varghese



Managing Editors:
Avais Raja
Orawan Chaigasame
Carrie Smith
Abdul Waheed
Khalid Alsayouri
Kyle Blair
Trevor Nezwek
Radia Jamil
Erin Hughes
Patrick Le
Anoosh Zafar Gondal
Saad Nazir
William Gossman
Hassam Zulfiqar
Navid Mahabadi
Hussain Sajjad
Steve Bhimji
Muhammad Hashmi
John Shell
Matthew Varacallo
Heba Mahdy
Ahmad Malik
Sarosh Vaqar
Mark Pellegrini
James Hughes
Beata Beatty
Daniyal Ameen
Altif Muneeb
Beenish Sohail
Nazia Sadiq
Hajira Basit
Phillip Hynes
Komal Shaheen
Sandeep Sekhon


Updated:
10/9/2019 2:00:19 PM

Indications

Memantine is an antagonist of the NMDA (N-Methyl-D-Aspartate)-receptor subtype of glutamate receptor. It is used to slow the neurotoxicity thought to be involved in Alzheimer disease and other neurodegenerative diseases.[1] Memantine blocks the NMDA-receptor subtype of glutamate receptors preventing over-activation of glutamine receptors while allowing the normal activity. Its blocking effects antagonize an overactive glutaminergic system in the central nervous system (CNS) which is thought to be involved in the neurotoxicity seen in Alzheimer disease.[2][3]

Pharmacologic Class

  • NMDA-receptor antagonist

Description

  • Chemical name: 1-amino-3,5-dimethyladamantane hydrochloride
  • Molecular formula: C12H21N•HCl
  • Molecular weight: 215.76

Food and Drug Administration (FDA) Indication[4]

  • Treatment of moderate to severe Alzheimer dementia

Other Uses (non-FDA approved)

  • Mild to moderate Alzheimer dementia
  • Mild to moderate vascular dementia
  • Chronic pain
  • Psychiatric disorders
  • Mild cognitive impairment

Diagnosis of Alzheimer Disease

  • The DSM-5 criteria for diagnosis include the following characteristics:
  1. Evidence of significant cognitive decline from a previous level of performance in one or more cognitive domains: complex attention, executive function, learning, and memory, language, perceptual-motor or social cognition
  2. The cognitive deficits interfere with independence in everyday activities
  3. The cognitive deficits do not occur only in the context of delirium
  4. Another mental disorder does not better explain the cognitive deficits
  5. The onset is an insidious and gradual progression of impairment in at least 2 cognitive domains:
  • Evidence of a causative Alzheimer disease genetic mutation from family history or genetic testing
  • All 3 of the following: Clear evidence of a decline in memory and learning and one or more other domains; steadily progressive, gradual decline in cognition, without extended plateaus; and no evidence of mixed etiology due to other neurodegenerative disorders or cerebrovascular disease.

Role of Memantine in Alzheimer Dementia

Alzheimer disease is a neurodegenerative disorder characterized by the presence of extracellular amyloid-beta protein an intracellular neurofibrillary tangle composed of hyperphosphorylated protein in the brain. There is a decrease in acetylcholine synthesis and impaired cortical cholinergic function in patients with Alzheimer dementia. So cholinesterase inhibitors (like donepezil, rivastigmine, galantamine) in dementia provide symptomatic relief by inhibiting cholinesterase at synaptic cleft and increasing cholinergic transmission. However, the mechanism of action of memantine is distinct from those of cholinergic agents and is proposed to be neuroprotective. Glutamate is a major excitatory neurotransmitter in the brain. One of the receptors activated by glutamate is the NMDA receptor which is essential for processes like learning and memory. Excessive activation of NMDARs been shown to be associated with neuronal loss/damage contributing to various acute and chronic neurological disorders including dementia. However physiological NMDA-receptor activity is also needed for normal neuronal function. Any agents that block all NMDA-receptor activity will have unacceptable clinical side effects. Memantine, through its action as an uncompetitive, low-affinity, open-channel blocker (uncompetitive antagonist of extrasynaptic NMDAR), preferentially enters the receptor-associated ion channel when it is excessively open, and hence, does not interfere with normal synaptic transmission. By doing so, it prevents or protects against further damage from neuronal cell death induced by excitotoxicity. Therefore, memantine is used for the treatment of Alzheimer dementia in combination with acetylcholinesterase inhibitors.[2]

Mechanism of Action

Memantine is an uncompetitive antagonist of the NMDA subtype of glutamate receptors in the CNS. Alzheimer disease is believed to be caused by overstimulation of glutamate, the primary excitatory amino acid in the CNS, resulting in excitotoxicity and neuronal degeneration. The NMDA receptor is a voltage-gated cation channel that in the physiologic unstimulated state is blocked by magnesium ions. Stimulated magnesium is displaced allowing calcium influx and activation. In Alzheimer disease, there is pathologic overstimulation of the receptor causing it to be in a chronically active state. Memantine helps to counteract the excessive stimulation.[1]

Memantine also exhibits antagonist activity at the serotonergic type 3 (5-HT3) and nicotinic acetylcholine receptors. It has no activity at the gamma-aminobutyric acid (GABA), benzodiazepine, dopamine, adrenergic, histamine, or glycine receptors or for voltage-dependent calcium, sodium, or potassium channels.[1]

Administration

Starting Dosage

  • 5 mg once daily

Target Dosage

  • 20 mg once daily

Titration

  • Dosage increased by 5 mg daily in weekly intervals as tolerated

Titration Schedule

  • Week 1: 5 mg daily
  • Week 2: 10 mg daily (5 mg twice daily)
  • Week 3: 15 mg daily (5 mg one time and 10 mg one time daily)
  • Week 4: 20 mg daily (10 mg twice daily) 

Switching from Immediate-Release (IR) to Extended-Release (ER)

  • Start ER day after the last dosage of IR; IR 10 mg twice daily should be switched to ER 28 mg daily

Missed Dosage

  • Single dose missed do not double up on next dose; if several dosages are missed, resume at a lower dose and titrate as tolerated

Special Population

  • Renal impairment: A target dose of 5 mg twice daily is recommended in patients with severe renal impairment (creatinine clearance of 5 to 29 mL per minutes based on the Cockroft-Gault equation)
  • Hepatic impairment: mild to moderate no dosage adjustment necessary; severe use with caution
  • Pregnancy: FDA category B (No evidence of risk in studies; animal reproduction studies have shown adverse events); use with caution
  • Breastfeeding: It is not known if memantine is excreted in breast milk; use with caution in nursing mother
  • Pediatric use: safety and effectiveness have not been established

Dosage Forms[3]

  • Capsule, extended-release, 24-hour, oral, as hydrochloride: Generic: 7 mg, 14 mg, 21 mg, 28 mg
  • Solution, oral, as hydrochloride: Generic: 2 mg/mL (360 mL)
  • Tablet, oral, as hydrochloride: Generic: 5 mg, 10 mg 

Administration

  • Any formulation: With or without food; do not chew, crush, or divide
  • Extended-release capsules: may be swallowed whole or entire contents of capsule sprinkled on food and swallowed immediately.
  • Oral Solution: Do not mix with any other liquid; administer with provided dosing device supplied with the device consisting of a syringe, syringe adaptor cap, tubing and other needed supplies; slowly squirt into the corner of the mouth

Storage

  • Room temperature between 20 C to 25 C (68 F to 77 F)

Adverse Effects

Most common in clinical trials: Dizziness, headache, confusion, diarrhea, and constipation[5]

Others: Fatigue, pain, hypertension, weight gain, hallucination, confusion, aggressive behavior, vomiting, abdominal pain, urinary incontinence

Uncommon (Post-marketing surveillance, clinical trials, or case reports): 

  • Neurologic: Abnormal gait, Cerebral infarction, Cerebrovascular accident, Intracranial hemorrhage, Seizure, Somnolence, Tardive dyskinesia
  • Cardiovascular: bradyarrhythmia, Heart failure, Myocardial infarction, peripheral edema, syncope, tachycardia
  • Endocrine: weight change
  • Gastrointestinal: Loss of appetite, nausea
  • Hematologic: anemia
  • Hepatic: Hepatitis, Liver failure
  • Renal: Acute renal failure, Urinary tract infection
  • Respiratory: Bronchitis, Pneumonia, Upper respiratory infection
  • Dermatologic: Rash, Stevens-Johnson syndrome
  • Musculoskeletal: Arthralgia
  • Others: Falling injury, Influenza-like symptoms, Neuroleptic malignant syndrome

Contraindications

Patients with hypersensitivity to memantine hydrochloride or any agents used in the formulation.

Warning/Precautions[5]

  • Genitourinary conditions: Conditions that raise urine pH may decrease the urinary elimination of memantine
  • Cardiovascular disease: Increased incidence of cardiac failure, angina, and hypertension occurred in clinical trials 
  • Hepatic impairment: Precaution use in severe hepatic impairment; effects of impairment on pharmacokinetics have not been established

Monitoring

No routine monitoring required for toxicity.

Monitoring Efficacy

  • Activities of daily living and cognitive functioning improvements 
  • Slowing in the progression of decline in cognitive function and memory impairment
  • It may take months for any noticeable improvement

Toxicity

Pharmacokinetics

Onset

  • Fourteen days (based on first improvements of Sandoz Clinical Assessment Geriatric [SCAG] scores compared to placebo)

Time to peak concentrations 

  • Three to 7 hours for oral immediate-release
  • Nine to 12 hours for oral extended-release 

Absorption

  • 100% (oral administration) with 100% bioavailability
  • Effects of food: immediate-release: no effect; extended-release: shown to decrease Tmax by 7 hours with no effect on AUC or Cmax 

Distribution

  • Volume of Distribution: 9 to 11 L/kg
  • Sites: 
  1. Protein-bound: 45%
  2. Brain: High concentration
  3. Kidney: High concentration
  4. Liver: Low concentration
  5. Lung: High concentration

Metabolism

  • Sites: Liver (partial): Hepatic CYP450 enzyme system does not play a significant role
  • Metabolites: All have minimal NMDA-receptor antagonist activity- N-glucuronide conjugate, 6-hydroxy memantine, and 1-nitroso-deaminated memantine

Excretion

  • Site: Renal 48% to 50% unchanged parent drug in urine involving active tubular secretion moderated by pH-dependent tubular reabsorption (reduced excretion by alkaline urine pH)

Time to Peak Concentrations

  • Three to seven hours for immediate-release 
  • Nine to twelve hours for extended-release

Terminal Elimination Half-Life

  • Sixty to 80 hours 

Enhancing Healthcare Team Outcomes

There is no cure for alzhemier disease and the few drugs available are only for mild cognitive impairment. Prescribers of memantine should be aware that the drug can worsen the symptoms of dementia. Hence, these patients should be closely monitored by the pharmacist, mental health nurse, psychiatrist and the primary care provider. The response to memantine is mild and most patients do not show any real benefit.[6][7][8]


Interested in Participating?

We are looking for contributors to author, edit, and peer review our vast library of review articles and multiple choice questions. In as little as 2-3 hours you can make a significant contribution to your specialty. In return for a small amount of your time, you will receive free access to all content and you will be published as an author or editor in eBooks, apps, online CME/CE activities, and an online Learning Management System for students, teachers, and program directors that allows access to review materials in over 500 specialties.

Improve Content - Become an Author or Editor

This is an academic project designed to provide inexpensive peer-reviewed Apps, eBooks, and very soon an online CME/CE system to help students identify weaknesses and improve knowledge. We would like you to consider being an author or editor. Please click here to learn more. Thank you for you for your interest, the StatPearls Publishing Editorial Team.

Memantine - Questions

Take a quiz of the questions on this article.

Take Quiz
Which was the first FDA approved drug to treat moderate to severe stages of Alzheimer disease?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which of the following medications helps in Alzheimer dementia?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which of the following mediations is approved for use in Alzheimer dementia?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which of the following Alzheimer treatments has a unique mechanism of action?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
For which condition is memantine used as a possible treatment?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
What is memantine's FDA approved indication?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
An 82-year-old lady with a diagnosis of moderate Alzheimer's dementia comes to your clinic for routine follow up visit accompanied by her daughter to discuss starting memantine. This was brought up because of recent worsening of her dementia, and cognitive testing showed progression of dementia into severe. She has been on donepezil 10 mg daily for her dementia without any side effects. Her other medical problems include hypertension, stage 4 chronic kidney disease, and osteoarthritis. Her other medications include amlodipine 5 mg daily and acetaminophen as needed for pain. Routine labs showed CBC with hemoglobin 12.5 g/dL (normal 12-15), hematocrit 36.2% (normal 36-45), WBC 5,000/microL (normal 4,500-10,000), platelets 200,000/microL (normal 150-400). Basic metabolic profile results showed sodium 135 mEQ/L (normal 135-145), potassium 4.2 mEq/L (normal 3.6-5.2), BUN 47 mg/dL (normal 7-25), creatinine 2.0 mg/dL (normal 0.4-1.0), and glucose 150 mg/dL. Creatinine clearance calculated at 23.97 ml/min. Based on the above information, which of the following is the best strategy to initiate immediate release memantine?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up

Memantine - References

References

The glutamatergic system and neurodegeneration in dementia: preventive strategies in Alzheimer's disease., Cacabelos R,Takeda M,Winblad B,, International journal of geriatric psychiatry, 1999 Jan     [PubMed]
The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease., Rogawski MA,Wenk GL,, CNS drug reviews, 2003 Fall     [PubMed]
Efficacy and tolerability of memantine in patients with dementia syndrome. A double-blind, placebo controlled trial., Ditzler K,, Arzneimittel-Forschung, 1991 Aug     [PubMed]
Wong KH,Riaz MK,Xie Y,Zhang X,Liu Q,Chen H,Bian Z,Chen X,Lu A,Yang Z, Review of Current Strategies for Delivering Alzheimer's Disease Drugs across the Blood-Brain Barrier. International journal of molecular sciences. 2019 Jan 17;     [PubMed]
Kennedy RE,Cutter GR,Fowler ME,Schneider LS, Association of Concomitant Use of Cholinesterase Inhibitors or Memantine With Cognitive Decline in Alzheimer Clinical Trials: A Meta-analysis. JAMA network open. 2018 Nov 2;     [PubMed]
Narayan SW,Pearson SA,Litchfield M,Le Couteur DG,Buckley N,McLachlan AJ,Zoega H, Anticholinergic medicines use among older adults before and after initiating dementia medicines. British journal of clinical pharmacology. 2019 May 2;     [PubMed]
McShane R,Westby MJ,Roberts E,Minakaran N,Schneider L,Farrimond LE,Maayan N,Ware J,Debarros J, Memantine for dementia. The Cochrane database of systematic reviews. 2019 Mar 20;     [PubMed]
Reeve E,Farrell B,Thompson W,Herrmann N,Sketris I,Magin PJ,Chenoweth L,Gorman M,Quirke L,Bethune G,Hilmer SN, Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary. The Medical journal of Australia. 2019 Mar;     [PubMed]

Disclaimer

The intent of StatPearls is to provide practice questions and explanations to assist you in identifying and resolving knowledge deficits. These questions and explanations are not intended to be a source of the knowledge base of all of medicine, nor is it intended to be a board or certification review. The authors or editors do not warrant the information is complete or accurate. The reader is encouraged to verify each answer and explanation in several references. All drug indications and dosages should be verified before administration.

StatPearls offers the most comprehensive database of free multiple-choice questions with explanations and short review chapters ever developed. This system helps physicians, medical students, dentists, nurses, pharmacists, and allied health professionals identify education deficits and learn new concepts. StatPearls is not a board or certification review system, it is a learning system that you can use to help improve your knowledge base of medicine for life-long learning. StatPearls will help you identify your weaknesses so that when you are ready to study for a board or certification exam, you will already be prepared.

Our content is updated continuously through a multi-step peer review process that will help you be prepared and review for a thorough knowledge of your specialty. When it is time for the board and certification exam, you will already be ready. Besides online study quizzes, we also publish our peer-reviewed content in eBooks and mobile Apps. We also offer inexpensive CME/CE, so our content can be used to attain education credits while you study.